Diamyd Medical, a Sweden-based company that develops precision medicine therapies for Type 1 Diabetes, announced on Monday that the US Food and Drug Administration (FDA) has withdrawn the partial clinical hold on the confirmatory Phase III trial DIAGNODE-3, assessing the safety and efficacy of the precision medicine and antigen-specific immunotherapy Diamyd in individuals recently diagnosed with type 1 diabetes.
Subsequent to the decision from the FDA, DIAGNODE-3 is approved to commence in the United States.
The FDA issued a partial clinical hold on the trial in September 2021, halting its commencement in the US. The company is to immediately resume the process of interacting with clinical sites and institutional review boards with the intention of including US clinical sites in the trial. The trial has been approved and is actively hiring patients in eight European countries.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients